Back

A Perk/Foxo1 Axis Links DNA Damage To Fibroblast Survival In Diffuse Cutaneous Systemic Sclerosis

Khan, L.; Wang, J.; Hunter, C.; Eeden, C. v.; Redmond, D.; Willis, L.; Durand, C.; Storek, J.; Jamani, K.; Mulder, U.; Baron, M.; Pope, J.; Netchiporouk, E.; Tervaert, J. W. C.; Vliagoftis, H.; Gniadecki, R.; Osman, M.

2026-02-18 molecular biology
10.64898/2026.02.17.706443 bioRxiv
Show abstract

ObjectiveDiffuse cutaneous systemic sclerosis (dcSSc) is a life-limiting fibrotic disease. We and others have shown that dcSSc fibroblasts accumulate numerous somatic mutations associated with senescence-like features; however, the mechanism(s) enabling their survival remain unclear. MethodsSkin biopsies were obtained from lesional tissues from dcSSc (n=10), dcSSc treated with autologous hematopoietic stem cell transplantation (ASCT, n=8) or 7 age/sex-matched healthy controls. Primary dermal fibroblasts were generated from biopsies. Spatial RNA sequencing, immunoblotting, confocal microscopy, and functional assays were used to mechanistically delineate signaling pathways linking DNA-damage with fibroblast survival. ResultsdcSSc fibroblasts demonstrated increased pH2AX DNA double-strand-break foci yet remained apoptosis resistant. These cells displayed features of metabolic-stress remodeling, including mitochondrial hyperpolarization, increased reactive oxygen species production, and enhanced mitochondrial biogenesis. Spatial transcriptomics and subsequent biochemical analyses identified activation of a PERK/ATF4/FOXO1 axis, characterized by PERK phosphorylation, selective ATF4 translation, FOXO1 nuclear translocation, and induction of downstream antioxidant and metabolic programs. In contrast, fibroblasts from post-ASCT patients exhibited normalization of DNA-damage markers and mitochondrial parameters without ATF4/FOXO1 activation. Pharmacologic inhibition of either PERK or FOXO1 selectively restored mitochondrial-dependent apoptosis in dcSSc fibroblasts, demonstrating that this axis is required for their survival following extensive genomic injury. ConclusiondcSSc fibroblasts persist despite substantial genomic injury by engaging a PERK/ATF4/FOXO1 metabolic-adaptation program that suppresses mitochondrial-dependent apoptosis. This survival axis is not present after ASCT. Targeting PERK or FOXO1 restores apoptosis selectively in dcSSc fibroblasts, highlighting its potential use as a therapeutic target for eliminating pathogenic senescence-like fibroblasts in dcSSc. HighlightsO_LIBoth ex-vivo skin and in-vitro primary dermal fibroblasts derived from dcSSc patients have a higher frequency of intrinsic DNA damage signals and senescence-associated features; yet they evade mitochondrial-dependent apoptosis. C_LIO_LIPathogenic dcSSc fibroblasts rewire their metabolism, characterized by mitochondrial hyperpolarization and elevated ROS. C_LIO_LISpatial transcriptomics and functional analyses reveal a PERK/ATF4/FOXO1 stress-adaptation axis that drives fibroblast survival in dcSSc. C_LIO_LIThis maladaptive survival program characterized by increased genotoxic stress, and mitochondrial remodelling is absent in post-ASCT fibroblasts. C_LIO_LITargeting PERK or FOXO1 selectively sensitizes dcSSc fibroblasts to apoptosis revealing a potential promising therapeutic strategy in dcSSc. C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=142 SRC="FIGDIR/small/706443v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@1b3f791org.highwire.dtl.DTLVardef@42548aorg.highwire.dtl.DTLVardef@bc4ce1org.highwire.dtl.DTLVardef@5b4d48_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Aging Cell
144 papers in training set
Top 0.6%
10.6%
2
Nature Communications
4913 papers in training set
Top 31%
5.1%
3
Arthritis & Rheumatology
33 papers in training set
Top 0.2%
4.5%
4
JCI Insight
241 papers in training set
Top 1.0%
4.2%
5
Journal of Investigative Dermatology
42 papers in training set
Top 0.2%
4.2%
6
GeroScience
97 papers in training set
Top 0.6%
3.4%
7
Cell Reports Medicine
140 papers in training set
Top 2%
3.2%
8
Journal of Translational Medicine
46 papers in training set
Top 0.3%
2.9%
9
eLife
5422 papers in training set
Top 31%
2.7%
10
EMBO Reports
88 papers in training set
Top 0.1%
2.2%
11
Cell Reports
1338 papers in training set
Top 21%
2.0%
12
European Respiratory Journal
54 papers in training set
Top 0.8%
2.0%
13
Clinical Epigenetics
53 papers in training set
Top 0.5%
1.9%
14
Stem Cell Research & Therapy
30 papers in training set
Top 0.4%
1.7%
50% of probability mass above
15
BMC Medical Genomics
36 papers in training set
Top 0.5%
1.6%
16
Stem Cells
28 papers in training set
Top 0.3%
1.6%
17
Neurobiology of Disease
134 papers in training set
Top 3%
1.4%
18
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.6%
1.4%
19
Nucleic Acids Research
1128 papers in training set
Top 13%
1.3%
20
Scientific Reports
3102 papers in training set
Top 65%
1.3%
21
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.2%
22
Aging
69 papers in training set
Top 2%
1.0%
23
EBioMedicine
39 papers in training set
Top 0.6%
1.0%
24
Journal of Advanced Research
15 papers in training set
Top 0.4%
1.0%
25
PLOS ONE
4510 papers in training set
Top 62%
1.0%
26
Cell Death Discovery
51 papers in training set
Top 0.9%
1.0%
27
The Journals of Gerontology: Series A
25 papers in training set
Top 0.7%
0.9%
28
Stem Cell Reports
118 papers in training set
Top 0.7%
0.9%
29
Blood
67 papers in training set
Top 1%
0.9%
30
Frontiers in Medicine
113 papers in training set
Top 6%
0.8%